Correction to: Leukemia (2006) 20, 1467–1473. doi:10.1038/sj.leu.2404284
It has been identified by the authors that there was an error in the author list. The following author was omitted in error.
M Cavo, Institute of Hematology and Medical Oncology ‘Seràgnoli’, University of Bologna, Italy.
The corrected list is mentioned here.
BGM Durie, J-L Harousseau, JS Miguel, J Bladé, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld, H Ludwig, G Gahrton, M Beksac, J Crowley, A Belch, M Boccadaro, M Cavo, I Turesson, D Joshua, D Vesole, R Kyle, R Alexanian, G Tricot, M Attal, G Merlini, R Powles, P Richardson, K Shimizu, P Tosi, G Morgan and SV Rajkumar on behalf of the International Myeloma Working Group.
The authors apologize for any inconvenience caused.
The online version of the original article can be found at 10.1038/sj.leu.2404284
About this article
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
British Journal of Haematology (2017)
Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Internal Medicine Journal (2015)
Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma
American Journal of Hematology (2014)
British Journal of Haematology (2013)
Expert Review of Hematology (2011)